SGLT-2 Inhibitor
Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study
... No serious adverse event was reported during this 3 month follow up. There was no hypoglycaemia reported. The commonest adverse event was nausea in 14 (23%) patients, 6 (20%) in the dulaglutide group compared to 8 ...
7
<p>The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers</p>
... of SGLT-2 inhi- bitors for renoprotection in patients with advanced-stage diabetic kidney ...of SGLT-2 inhibitor use in patients with moderate-to-severe chronic kidney disease taking ...
11
Prolonged diabetic ketoacidosis associated with canagliflozin
... We report a case of a 63-year-old man who developed diabetic ketoacidosis (DKA) associated with canagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor. He presented acutely unwell ...
5
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
... when SGLT-2 inhibitors are associated with insulin therapy, may not be sufficient to block gluconeogenesis in the liver, with a net consumption of oxaloacetate (for gluconeogenesis) impeding the entrance of ...
14
The effect of dapagliflozin treatment on epicardial adipose tissue volume
... an SGLT-2 inhibitor reduced the occurrence of cardiovas- cular events [13, ...an SGLT-2 inhibitor include: improvement in glucose perturbations and insu- lin sensitivity; ...
9
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
... of 2 years in patients at lower risk. The results of the SGLT-2 inhibitors may be limited by the relatively low number of patients and events in the SGLT-2 inhibitor ...
11
<p>Canagliflozin review – safety and efficacy profile in patients with T2DM</p>
... was the first SGLT-2 inhibitor to be approved in 2013. As canagliflozin has had more time on the market, there are more opportunities to study it in real-world settings (Table 6). The safety and ...
7
Practical combination therapy based on pathophysiology of type 2 diabetes
... DPP-4 inhibitor, and an SGLT-2 inhibitor has also been shown to be efficacious in reducing A1C without increasing the risk for hypoglycemia or weight ...
15
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
... of SGLT-2 inhibitors—with larger sample sizes—have demonstrated that SGLT-2 inhibitors elevate LDL-C levels [5, ...with SGLT-2 ...that SGLT-2 inhibitors reduce TG ...
13
Need of the hour: pharmacovigilance study of SGLT-2 inhibitors
... individual SGLT-2 inhibitors various ADRs is conflicting and most RCTs compare individual SGLT-2 inhibitors with ...the SGLT-2 ...each SGLT-2 inhibitor for ...
5
<p>Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice</p>
... of SGLT-2i to cut down the BP is not entirely dependent on the circulation volume depletion in such short ...that SGLT-2i reduces BP but does not elevate or slow down the HR, and therefore this effect may ...
19
Imbalance of tissue inhibitors of metalloproteinases (TIMP) – 1 and – 4 serum levels, in patients with inflammatory bowel disease
... The TIMP-1 levels in the mucosa and plasma of IBD patients have been shown to be elevated, in previous stud- ies [5-8]. Moreover, the TIMP-1 plasma levels demon- strate a significant positive correlation with the ...
8
The Distribution of Matrix Metalloproteinase-2, Tissue Inhibitor of Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-4 in Psoriatic Skin
... We found increased expression of MMP-2 in psoriatic epidermis, epidermal appendages and dermis. This is in agreement with previous studies of MMP-2 in psoriasis patients with a history of diabetes and ...
8
Prospective Study on Prescribing Pattern and Short-Term Outcomes of SGLT-2 Inhibitors in a Tertiary Care Hospital
... Inhibitors of sodium-glucose cotransporters type-2 (SGLT-2) are new glucose-lowering agents with an original insulin-independent mode of action developed for the treatment of type-II diabetes ...
99
<p>Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence</p>
... In the proximal tubule of kidney, the reabsorption of glucose is coupled with the reabsorption of sodium. Inhibition of SGLT2 results in natriuresis and osmotic diuresis and, sub- sequently, in reduction of plasma and ...
14
REVIEW ONPHARMACOKINETICS OF EMPAGLIFLOZIN, AN INHIBITOR OF THE SODIUM GLUCOSE CO TRANSPORTER 2 (SGLT 2)
... The type 2 diabetes is a chronic metabolic disorder triggered by insulin insensitivity and reduced level of insulin secretion. Insulin is a hormone that plays a key role in the transport of glucose to organs like ...
7
Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases
... Moreover, the function of BMP-2 raises the possibility of cancer promotion since BMP-2 and its receptors are highly expressed in many human cancers [17]. For instance, Kokorina et al. reported that ...
13
Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1
... In summary, results of our study are reassuring in terms cardiovascular and neoplastic safety of radioiodine treat- ment of thyrotoxicosis. In particular, administration of radioiodine does not alter serum concentrations ...
7
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non small cell lung cancer and ovarian cancer: a systematic review
... 11 studies which provided separate data for the platinum-refractory cohort, the overall response rate was similar, being 10% (16 responders/ 160 patients) (Shepard et al., 2005; Felip et al., 2008). This suggests that it ...
44
A 2 Pyridone Amide Inhibitor Targets the Glucose Metabolism Pathway of Chlamydia trachomatis
... (Fig. 2, middle row), possibly indi- cating that these compounds interfere with acquisition of building blocks required for RB enlargement in response to penicillin-G ...
9